MX2020001157A - Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). - Google Patents
Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc).Info
- Publication number
- MX2020001157A MX2020001157A MX2020001157A MX2020001157A MX2020001157A MX 2020001157 A MX2020001157 A MX 2020001157A MX 2020001157 A MX2020001157 A MX 2020001157A MX 2020001157 A MX2020001157 A MX 2020001157A MX 2020001157 A MX2020001157 A MX 2020001157A
- Authority
- MX
- Mexico
- Prior art keywords
- sup
- compounds
- isochromanyl
- heterocyclyl
- analogs
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos de la Fórmula (I): (ver Fórmula) y sales farmacéuticamente aceptables de los mismos, en donde A, Ra, R1, R2, R3, R4, R6, w y n1 se definen y describen en la presente; composiciones de los mismos; y métodos de uso de los mismos. Estos compuestos son útiles para tratar una variedad de trastornos neurológicos y psiquiátricos, tales como los descritos aquí.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562115064P | 2015-02-11 | 2015-02-11 | |
PCT/US2016/017539 WO2016130796A1 (en) | 2015-02-11 | 2016-02-11 | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001157A true MX2020001157A (es) | 2022-05-27 |
Family
ID=55456908
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001157A MX2020001157A (es) | 2015-02-11 | 2016-02-11 | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). |
MX2017010363A MX371404B (es) | 2015-02-11 | 2016-02-11 | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010363A MX371404B (es) | 2015-02-11 | 2016-02-11 | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). |
Country Status (21)
Country | Link |
---|---|
US (4) | US9856238B2 (es) |
EP (2) | EP3256466B9 (es) |
JP (3) | JP6657241B2 (es) |
KR (1) | KR102601972B1 (es) |
CN (2) | CN111925360B (es) |
AU (1) | AU2016219253C1 (es) |
CA (1) | CA2976095C (es) |
DK (1) | DK3256466T3 (es) |
EA (1) | EA201791804A1 (es) |
ES (2) | ES2967643T3 (es) |
HU (1) | HUE058698T2 (es) |
IL (1) | IL253914B (es) |
MX (2) | MX2020001157A (es) |
MY (1) | MY188160A (es) |
NZ (1) | NZ735011A (es) |
PH (1) | PH12017501422A1 (es) |
PL (1) | PL3256466T3 (es) |
PT (1) | PT3256466T (es) |
SG (2) | SG11201706515QA (es) |
UA (1) | UA122222C2 (es) |
WO (1) | WO2016130796A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016219247B2 (en) * | 2015-02-11 | 2020-08-13 | Pgi Drug Discovery Llc | Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders |
EP3256466B9 (en) * | 2015-02-11 | 2022-07-27 | Sunovion Pharmaceuticals Inc. | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
EP3490607A4 (en) | 2016-07-29 | 2020-04-08 | Sunovion Pharmaceuticals Inc. | COMPOUNDS AND COMPOSITIONS, AND USES THEREOF |
WO2018023072A2 (en) | 2016-07-29 | 2018-02-01 | Sunovion Pharmaceuticals, Inc. | Compounds and compositions and uses thereof |
US11266633B2 (en) | 2017-06-30 | 2022-03-08 | Chase Therapeutics Corporation | NK-1 antagonist compositions and methods for use in treating depression |
JP7191085B2 (ja) | 2017-08-02 | 2022-12-16 | サノビオン ファーマシューティカルズ インク | イソクロマン化合物およびその使用 |
MX2021010880A (es) | 2019-03-14 | 2022-01-18 | Sunovion Pharmaceuticals Inc | Sales de un compuesto de isocromanilo y formas cristalinas, procesos de preparacion, usos terapeuticos y composiciones farmaceuticas de las mismas. |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3438995A (en) | 1968-01-08 | 1969-04-15 | Melville Sahyun | Diazaheterocyclic substituted benz-oxaheterocyclic compounds |
US5621133A (en) | 1989-05-31 | 1997-04-15 | Deninno; Michael P. | Dopamine agonists |
US4963568A (en) | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
IE73232B1 (en) * | 1990-05-25 | 1997-05-21 | Akzo Nv | Isochromane derivatives |
US5238939A (en) * | 1990-05-25 | 1993-08-24 | Akzo N.V. | Isochromane derivatives |
CA2336254A1 (en) | 1998-06-30 | 2000-01-06 | Daniel James Koch | 5-ht1f agonists |
SE9902267D0 (sv) | 1999-06-16 | 1999-06-16 | Astra Ab | New compounds |
JP2005510518A (ja) * | 2001-11-08 | 2005-04-21 | セプラコール, インク. | シタロプラムのデスメチル代謝産物及びジデスメチル代謝産物の濃縮された鏡像異性体を用いてうつ病及び他のcns障害を治療する方法 |
KR100965190B1 (ko) * | 2004-12-21 | 2010-06-24 | 에프. 호프만-라 로슈 아게 | 크로만 유도체 및 중추 신경계 장애의 치료에서 그의 용도 |
CA2605587A1 (en) | 2005-04-22 | 2006-11-02 | Wyeth | Chromane and chromene derivatives and uses thereof |
CA2637261A1 (en) * | 2006-01-27 | 2007-08-02 | F. Hoffmann-La Roche Ag | Use of 2-imidazoles for the treatment of cns disorders |
KR101103118B1 (ko) | 2007-11-02 | 2012-01-04 | 동아제약주식회사 | 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물 |
SG181498A1 (en) | 2009-12-04 | 2012-07-30 | Sunovion Pharmaceuticals Inc | Multicyclic compounds and methods of use thereof |
EP2683710B1 (en) | 2011-03-10 | 2017-07-19 | Boehringer Ingelheim International GmbH | Soluble guanylate cyclase activators |
AR090557A1 (es) | 2012-04-02 | 2014-11-19 | Orion Corp | DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2 |
CA2896871A1 (en) * | 2012-12-31 | 2014-07-03 | Kerry L. Spear | Heterocyclic compounds and methods of use thereof |
EP3256466B9 (en) * | 2015-02-11 | 2022-07-27 | Sunovion Pharmaceuticals Inc. | 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders |
-
2016
- 2016-02-11 EP EP16708262.7A patent/EP3256466B9/en active Active
- 2016-02-11 SG SG11201706515QA patent/SG11201706515QA/en unknown
- 2016-02-11 JP JP2017542401A patent/JP6657241B2/ja active Active
- 2016-02-11 PT PT167082627T patent/PT3256466T/pt unknown
- 2016-02-11 CN CN202010607608.6A patent/CN111925360B/zh active Active
- 2016-02-11 DK DK16708262.7T patent/DK3256466T3/da active
- 2016-02-11 ES ES22166538T patent/ES2967643T3/es active Active
- 2016-02-11 US US15/041,852 patent/US9856238B2/en active Active
- 2016-02-11 CA CA2976095A patent/CA2976095C/en active Active
- 2016-02-11 AU AU2016219253A patent/AU2016219253C1/en active Active
- 2016-02-11 KR KR1020177025290A patent/KR102601972B1/ko active IP Right Grant
- 2016-02-11 PL PL16708262T patent/PL3256466T3/pl unknown
- 2016-02-11 UA UAA201708945A patent/UA122222C2/uk unknown
- 2016-02-11 WO PCT/US2016/017539 patent/WO2016130796A1/en active Application Filing
- 2016-02-11 MX MX2020001157A patent/MX2020001157A/es unknown
- 2016-02-11 ES ES16708262T patent/ES2911910T3/es active Active
- 2016-02-11 EP EP22166538.3A patent/EP4046995B1/en active Active
- 2016-02-11 SG SG10201806809QA patent/SG10201806809QA/en unknown
- 2016-02-11 MX MX2017010363A patent/MX371404B/es active IP Right Grant
- 2016-02-11 MY MYPI2017702923A patent/MY188160A/en unknown
- 2016-02-11 NZ NZ735011A patent/NZ735011A/en unknown
- 2016-02-11 HU HUE16708262A patent/HUE058698T2/hu unknown
- 2016-02-11 EA EA201791804A patent/EA201791804A1/ru unknown
- 2016-02-11 CN CN201680018639.XA patent/CN107531674B/zh active Active
-
2017
- 2017-08-08 IL IL253914A patent/IL253914B/en unknown
- 2017-08-09 PH PH12017501422A patent/PH12017501422A1/en unknown
- 2017-11-21 US US15/819,372 patent/US10336732B2/en active Active
-
2019
- 2019-05-06 US US16/403,698 patent/US11192885B2/en active Active
-
2020
- 2020-02-05 JP JP2020018081A patent/JP7023994B2/ja active Active
-
2021
- 2021-10-29 US US17/452,786 patent/US20220185799A1/en active Pending
-
2022
- 2022-02-09 JP JP2022018580A patent/JP2022065050A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021013075A (es) | Oxisteroles y metodos de uso de los mismos. | |
MX2020011449A (es) | Oxiesteroles y metodos de uso de los mismos. | |
MX2020001157A (es) | Compuestos y analogos de 1-heterociclil isocromanilo para el tratamiento de trastornos del sistema nervioso central (snc). | |
MX2020010690A (es) | Oxiesteroles y metodos de uso de los mismos. | |
MX2023005098A (es) | Composiciones y usos de las mismas para el tratamiento de trastornos en el sistema nervioso central. | |
MX2021004492A (es) | Composiciones para el tratamiento de trastornos del snc. | |
MX2023002004A (es) | Composiciones y metodos para el tratamiento de trastornos en el sistema nervioso central. | |
EP4316591A3 (en) | Oxysterols and methods of use thereof | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
MY202022A (en) | Pyrrolotriazine compounds as tam inhibitors | |
MX2023001876A (es) | Derivados de rapamicina. | |
PH12017501423A1 (en) | Fused dihydro-4h-pyrazolo[5,1-c][1,4]oxazinyl compounds and analogs for treating cns disorders | |
TN2016000529A1 (en) | Substituted dihydroisoquinolinone compounds | |
MX2020001832A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
PH12017502009A1 (en) | Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection | |
MX2022005024A (es) | Profarmacos de fosforo de estimuladores de guanilato ciclasa soluble (sgc). | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
MX2017013103A (es) | Metodos para el tratamiento de trastornos cardiovasculares. |